WASHINGTON, Aug 3 (Reuters) - The decision whether the U.S. Food and Drug Administration should approve wider access to a morning-after contraceptive drug was made well before agency scientists finished their final review, two FDA officials said in court documents released on Thursday.>>> Discuss This Story
